{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lindahl LM"],"funding":["LEO Foundation Skin Immunology Research Center","The Danish Cancer Society","NCI NIH HHS","Novo Nordisk Fonden","Lundbeck Foundation"],"pagination":["1072-1083"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6764271"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["134(13)"],"pubmed_abstract":["It has been proposed that CD4 T-cell responses to <i>Staphylococcus aureus</i> (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL."],"journal":["Blood"],"pubmed_title":["Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma."],"pmcid":["PMC6764271"],"funding_grant_id":["Bonefeld-Geisler Group","R204-A12565","NNF15OC0018774","R167-A11085","R72-A4571","R198-2015-486","R231-2016-2628","R132-A8475","P30 CA006927","Woetmann-Ødum Group"],"pubmed_authors":["Gluud M","Woetmann A","Geisler C","Blumel E","Bzorek M","Krejsgaard T","Willerslev-Olsen A","Bonefeld CM","Peiffer L","Litman T","Wasik MA","Langhoff E","Kubat L","Fredholm S","Nielsen PR","Stausbol-Gron B","Eriksen JO","Givskov M","Lindahl LM","Rittig AH","Nastasi C","Herpers B","Kilian M","Johansen C","Celis P","Buus TB","Gjerdrum LMR","Mustelin T","Odum N","Iversen L","Becker JC"],"additional_accession":[]},"is_claimable":false,"name":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.","description":"It has been proposed that CD4 T-cell responses to <i>Staphylococcus aureus</i> (SA) can inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T-cell lymphoma (CTCL). In this prospective study, we explored the effect of transient antibiotic treatment on tumor cells and disease activity in 8 patients with advanced-stage CTCL. All patients experienced significant decrease in clinical symptoms in response to aggressive, transient antibiotic treatment. In some patients, clinical improvements lasted for more than 8 months. In 6 of 8 patients, a malignant T-cell clone could be identified in lesional skin, and a significant decrease in the fraction of malignant T cells was observed following antibiotics but an otherwise unchanged treatment regimen. Immunohistochemistry, global messenger RNA expression, and cell-signaling pathway analysis indicated that transient aggressive antibiotic therapy was associated with decreased expression of interleukin-2 high-affinity receptors (CD25), STAT3 signaling, and cell proliferation in lesional skin. In conclusion, this study provides novel evidence suggesting that aggressive antibiotic treatment inhibits malignant T cells in lesional skin. Thus, we provide a novel rationale for treatment of SA in advanced CTCL.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2024-10-18T06:12:01.146Z","creation":"2020-09-30T07:03:35Z"},"accession":"S-EPMC6764271","cross_references":{"pubmed":["31331920"],"doi":["10.1182/blood.2018888107"]}}